



EQT
Life Sciences

EQT

Advanced Therapeutic Medicinal Products

An Investor's perspective

4 April 2023

Several numbers of Cell & Gene Therapies

~23B USD


Two-thirds of venture capital financing went into Cell & Gene Therapies in 2021

52%

(~ 1250)
Of development programs are in oncology

27

Approved Products as of February 2023





The investor's perspective



The investor's perspective



What is the **context** that we operate in?



What are the **Inherent risk factors** for ATMPs?



What are the **external risk factors** for ATMPs?